New pain pump could cut narcotic use after hysterectomy
NCT ID NCT04130464
First seen Apr 14, 2026 · Last updated Jun 22, 2026 · Updated 16 times
Summary
This study tests whether a continuous pump delivering pain medicine into the abdomen can lower pain and reduce the need for narcotics after minimally invasive hysterectomy. About 120 women having surgery for non-cancer reasons will receive either a numbing medicine, a numbing medicine plus an anti-inflammatory, or a placebo for 72 hours after surgery. Pain levels and total painkiller use will be tracked.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAIN, POSTOPERATIVE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MedStar Washington Hospital Center
RECRUITINGWashington D.C., District of Columbia, 20010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The GW Medical Faculty Associates
RECRUITINGWashington D.C., District of Columbia, 20037, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ropivacaine and ketorolac
What this could lead to
If it works, this could offer a better way to manage pain after hysterectomy and reduce the need for narcotics.
What could go wrong
This is a Phase 4 trial with 120 participants, so results may not apply to everyone. The pain pump itself could cause discomfort or infection.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.